Medtronic (NYSE:MDT) Posts Earnings Results, Beats Expectations By $0.02 EPS

Medtronic (NYSE:MDT) posted its quarterly earnings results on Tuesday. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02, FiscalAI reports. The company had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.38 EPS. Medtronic updated its FY 2026 guidance to 5.620-5.660 EPS.

Here are the key takeaways from Medtronic’s conference call:

• Symplicity Spyral is positioned as a major growth driver with strong early demand (direct-to-consumer campaign drove a ~50x increase in site visits), expanding reimbursement (~100M covered lives) and growing clinical/physician adoption (200+ new accounts, physician finder >150).
• UltraViva tibial neurostimulation shows early commercial traction—the company has trained 500+ physicians, highlights product advantages (no imaging/sedation, same‑day activation, up to 15-year battery) and is investing in omni-channel consumer and hospital support to scale procedures.
• The Hugo surgical robot received FDA clearance for urologic procedures and already completed first U.S. installations/cases (Cleveland Clinic); Medtronic pairs Hugo with its Touch Surgery ecosystem (installations +20% sequentially, >1,000 systems globally) to drive adoption.
• The Stealth AXiS system secured FDA clearance for spinal procedures, integrating AI planning, navigation and robotics into one workflow that targets the 70% of U.S. spine cases using navigation and is expected to contribute to CST results as soon as Q4.
• Q3 revenue beat—$9.0B, +8.7% reported and +6% organic—and FY26 organic growth guidance (~5.5%) was reiterated, but margins face headwinds from tariffs (~$185M FY26) and unfavorable mix (CAS and diabetes), while FY27 EPS guidance targets high single‑digit growth with some temporary dilution from the planned diabetes separation and M&A.

Medtronic Price Performance

Shares of NYSE:MDT opened at $96.33 on Wednesday. The stock has a market cap of $123.50 billion, a PE ratio of 25.96, a price-to-earnings-growth ratio of 2.62 and a beta of 0.71. The business’s fifty day moving average price is $99.19 and its two-hundred day moving average price is $96.58. Medtronic has a one year low of $79.55 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s dividend payout ratio is presently 76.55%.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 beat: Medtronic topped consensus on revenue ($9.02B) and adjusted EPS ($1.36), driven by stronger demand in heart devices and diabetes, which underpins near‑term cash flow and credibility with investors. Article Title
• Positive Sentiment: Cardiovascular & ablation strength: Cardiac Ablation Solutions grew rapidly (PFA portfolio), with U.S. ablations more than doubling — a high‑growth end market boosting revenue mix and investor sentiment. Article Title
• Positive Sentiment: Regulatory and product catalysts: FDA clearances and commercial milestones — including the first U.S. surgery with the Hugo robotic system and new clearances for spine and bone‑graft uses — add new revenue levers. Article Title
• Positive Sentiment: Analyst / technical support: TD Cowen reiterated a Buy with a $119 target and technical/institutional accumulation stories argue for further upside into mid‑year. Article Title
• Neutral Sentiment: Guidance reaffirmed: Management kept FY26 EPS guidance near prior range (5.620–5.660) — in line with consensus and reducing forecast risk but offering limited upside surprise. Article Title
• Neutral Sentiment: Capital allocation & M&A: Continued buybacks/dividend support and strategic deals (CathWorks, Anteris) signal management is executing on growth and returns — longer‑term positives but not immediate catalysts. Article Title
• Negative Sentiment: Margin pressure / costs: Reported profit fell on higher costs, tariff headwinds and investment spending; adjusted margins contracted, which caps near‑term operating leverage. Article Title
• Negative Sentiment: Guidance reaction risk: Because the company only reaffirmed guidance (versus raising it), some investors sold into the print — keeping volatility intact despite the beat. Article Title

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of MDT. Acumen Wealth Advisors LLC purchased a new position in Medtronic during the fourth quarter worth about $29,000. Imprint Wealth LLC acquired a new position in shares of Medtronic during the third quarter worth about $31,000. Chapman Financial Group LLC purchased a new position in Medtronic in the 2nd quarter worth approximately $37,000. JPL Wealth Management LLC purchased a new position in shares of Medtronic in the third quarter valued at $40,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Medtronic by 96.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 454 shares of the medical technology company’s stock valued at $44,000 after acquiring an additional 223 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have commented on MDT. Sanford C. Bernstein lifted their price target on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. CICC Research started coverage on shares of Medtronic in a research report on Friday, January 30th. They set an “outperform” rating on the stock. Finally, Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Sixteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $111.32.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).